681 related articles for article (PubMed ID: 28321813)
41. Ab therapy of AML: native anti-CD33 Ab and drug conjugates.
Jurcic JG
Cytotherapy; 2008; 10(1):7-12. PubMed ID: 17917880
[TBL] [Abstract][Full Text] [Related]
42. Monoclonal Antibodies in Acute Myeloid Leukemia-Are We There Yet?
Abaza Y; Fathi AT
Cancer J; 2022 Jan-Feb 01; 28(1):37-42. PubMed ID: 35072372
[TBL] [Abstract][Full Text] [Related]
43. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome.
Matthews DC
Leukemia; 1998 Sep; 12 Suppl 1():S33-6. PubMed ID: 9777893
[TBL] [Abstract][Full Text] [Related]
44. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
45. Monoclonal antibodies for the treatment of acute myeloid leukemia.
Abutalib SA; Tallman MS
Curr Pharm Biotechnol; 2006 Oct; 7(5):343-69. PubMed ID: 17076651
[TBL] [Abstract][Full Text] [Related]
46. Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?
Spillane DR; Assouline S
Expert Rev Hematol; 2023; 16(11):819-834. PubMed ID: 37819154
[TBL] [Abstract][Full Text] [Related]
47. Immune-Based Therapies in Acute Leukemia.
Witkowski MT; Lasry A; Carroll WL; Aifantis I
Trends Cancer; 2019 Oct; 5(10):604-618. PubMed ID: 31706508
[TBL] [Abstract][Full Text] [Related]
48. Immunotherapy in NSCLC: A Promising and Revolutionary Weapon.
Rolfo C; Caglevic C; Santarpia M; Araujo A; Giovannetti E; Gallardo CD; Pauwels P; Mahave M
Adv Exp Med Biol; 2017; 995():97-125. PubMed ID: 28321814
[TBL] [Abstract][Full Text] [Related]
49. Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia
Rennert PD; Dufort FJ; Su L; Sanford T; Birt A; Wu L; Lobb RR; Ambrose C
Mol Cancer Ther; 2021 Oct; 20(10):2071-2081. PubMed ID: 34253594
[TBL] [Abstract][Full Text] [Related]
50. Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition.
Greiner J; Götz M; Hofmann S; Schrezenmeier H; Wiesneth M; Bullinger L; Döhner H; Schneider V
Cancer Immunol Immunother; 2020 Apr; 69(4):629-640. PubMed ID: 32020256
[TBL] [Abstract][Full Text] [Related]
51. CD33-Targeted Therapies: Beating the Disease or Beaten to Death?
Maakaron JE; Rogosheske J; Long M; Bachanova V; Mims AS
J Clin Pharmacol; 2021 Jan; 61(1):7-17. PubMed ID: 32875599
[TBL] [Abstract][Full Text] [Related]
52. Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia.
Ganesan R; Chennupati V; Ramachandran B; Hansen MR; Singh S; Grewal IS
Leukemia; 2021 Aug; 35(8):2274-2284. PubMed ID: 33526858
[TBL] [Abstract][Full Text] [Related]
53. Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies.
Chen EC; Garcia JS
Acta Haematol; 2024; 147(2):198-218. PubMed ID: 37673048
[TBL] [Abstract][Full Text] [Related]
54. Nursing implications of mylotarg: a novel antibody-targeted chemotherapy for CD33+ acute myeloid leukemia in first relapse.
Shannon-Dorcy K
Oncol Nurs Forum; 2002 May; 29(4):E52-9. PubMed ID: 12011919
[TBL] [Abstract][Full Text] [Related]
55. Immune Therapy for Sarcomas.
Anderson PM
Adv Exp Med Biol; 2017; 995():127-140. PubMed ID: 28321815
[TBL] [Abstract][Full Text] [Related]
56. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F
Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302
[TBL] [Abstract][Full Text] [Related]
57. Novel monoclonal antibody-based therapies for acute myeloid leukemia.
Morsink LM; Walter RB
Best Pract Res Clin Haematol; 2019 Jun; 32(2):116-126. PubMed ID: 31203993
[TBL] [Abstract][Full Text] [Related]
58. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
59. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
Williams P; Basu S; Garcia-Manero G; Hourigan CS; Oetjen KA; Cortes JE; Ravandi F; Jabbour EJ; Al-Hamal Z; Konopleva M; Ning J; Xiao L; Hidalgo Lopez J; Kornblau SM; Andreeff M; Flores W; Bueso-Ramos C; Blando J; Galera P; Calvo KR; Al-Atrash G; Allison JP; Kantarjian HM; Sharma P; Daver NG
Cancer; 2019 May; 125(9):1470-1481. PubMed ID: 30500073
[TBL] [Abstract][Full Text] [Related]
60. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
Stadtmauer EA
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
